RecruitingPhase 1NCT07401680

Fecal Microbiota Transplantation in an Expanded Ulcerative Colitis Population

A Multi-centre, Randomised Controlled Trial Comparing Fecal Microbiota Transplantation to Placebo in an Expanded Ulcerative Colitis Population: a Feasibility Study (FRONTIER-UC)

Sponsor

University of Alberta

Enrollment

85 participants

Start Date

Mar 1, 2026

Study Type

INTERVENTIONAL

Conditions

Ulcerative Colitis Inflammatory Bowel Diseases Clostridioides Difficile Infection

Summary

This is a multi-centre, randomised controlled trial comparing fecal microbiota transplantation to placebo in an expanded ulcerative colitis population: a feasibility study (FRONTIER-UC) to determine whether a full-scale randomized controlled trial (RCT) to investigate fecal microbiota transplantation (FMT) in ulcerative colitis (UC) is feasible.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Lyophilized Fecal Microbiota Transplantation (LFMT) and Placebo for people with clostridioides difficile infection, inflammatory bowel diseases, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERLyophilized Fecal Microbiota Transplantation (LFMT)

LFMT by oral capsules

OTHERPlacebo

Placebo capsules does not contain FMT

Locations(2)

University of Calgary

Calgary, Alberta, Canada

University of Alberta

Edmonton, Alberta, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07401680

Related Trials

A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting

NCT06581328101 locations

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

NCT06979336101 locations

Role of Bile Acids and Microbiota in Clostridioides Difficile Infection in Ulcerative Colitis

NCT062283521 location

A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

NCT0707151953 locations

Resting Energy Expenditure in Pediatric Patients With Inflammatory Bowel Disease (REE-MICI)

NCT076709751 location